This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Chinese Clinical Trial Registry | |
|---|---|
| Name | Chinese Clinical Trial Registry |
| Formation | 2005 |
| Headquarters | Beijing |
| Leader title | Director |
Chinese Clinical Trial Registry is a primary registry for clinical trials based in Beijing and recognized by the World Health Organization International Clinical Trials Registry Platform as part of an international effort to improve trial transparency. It serves as a repository for interventional and observational studies conducted in the People's Republic of China, linking researchers from institutions such as the Peking University and Tsinghua University with regulatory agencies like the National Medical Products Administration and the National Health Commission. The registry interacts with global actors including the Cochrane Collaboration, the International Committee of Medical Journal Editors, and the World Medical Association.
The registry was established in the mid-2000s amid international initiatives following high-profile events such as the Declaration of Helsinki revisions and the adoption of the International Committee of Medical Journal Editors registration requirement. Early development involved collaborations with the World Health Organization and academic partners from Peking Union Medical College and Fudan University Medical School. Milestones include alignment with the WHO International Clinical Trials Registry Platform and policy shifts influenced by incidents like the He Jiankui affair and domestic responses to outbreaks such as COVID-19 pandemic in mainland China. The registry evolved alongside reforms in the National Medical Products Administration and was shaped by global standards from entities including the U.S. Food and Drug Administration, the European Medicines Agency, and the Council for International Organizations of Medical Sciences.
Governance involves collaboration among research institutions including Zhongshan Hospital, regulatory bodies like the National Health Commission, and ethics committees at hospitals such as West China Hospital. Administrative oversight has ties to academic centers like Shanghai Jiao Tong University School of Medicine and policy frameworks referenced by organizations such as the World Health Organization and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Leadership interacts with funders and stakeholders including the National Natural Science Foundation of China and university research offices at Sun Yat-sen University and Nanjing University Medical School.
Researchers from institutions such as Zhejiang University School of Medicine, Sichuan University and Harbin Medical University submit trial protocols, which are evaluated in light of international norms like the Declaration of Helsinki and guidance from the International Committee of Medical Journal Editors. Required fields mirror datasets recommended by the WHO Trial Registration Data Set and align with standards from the U.S. National Institutes of Health and the European Medicines Agency. Policies address registration timing influenced by editorials in journals such as The Lancet, New England Journal of Medicine, and BMJ and by directives from bodies like the Chinese Center for Disease Control and Prevention and the National Medical Products Administration. The registry records sponsor information from entities including GlaxoSmithKline, Pfizer, and domestic companies like Sinopharm when applicable.
The platform provides searchable metadata comparable to tools at the WHO International Clinical Trials Registry Platform, the European Union Clinical Trials Register, and the U.S. ClinicalTrials.gov portal maintained by the National Library of Medicine. Users from institutions such as Peking University Health Science Center and Capital Medical University can query trial identifiers, enrollment figures, and outcome measures using filters influenced by standards from the Cochrane Collaboration and analytics practices seen in repositories like the ICPSR. Integration efforts reference data exchange approaches used by the Global Health Network and interoperability principles advocated by the World Health Organization.
Quality controls draw on Good Clinical Practice guidelines from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and ethical frameworks like the Declaration of Helsinki and the Nuremberg Code; institutional review boards at hospitals such as Peking Union Medical College Hospital and Tongji Hospital review protocols prior to registration. Oversight includes audit trails akin to those used by the U.S. Food and Drug Administration inspection programs and reporting expectations discussed in journals like JAMA and The Lancet. The registry's procedures intersect with national regulatory reforms by the National Medical Products Administration and compliance guidance from the Chinese Center for Disease Control and Prevention.
The registry has supported transparency in trials conducted at centers such as Ruijin Hospital, Zhongnan Hospital of Wuhan University, and Beijing Tiantan Hospital, informing systematic reviews by the Cochrane Collaboration and meta-analyses published in The Lancet and BMJ. During public health emergencies—most notably the COVID-19 pandemic in mainland China—the registry was used to register vaccine and therapeutic trials involving institutions like Wuhan Institute of Virology and companies such as Sinovac Biotech. Its records have been cited in policy deliberations at the World Health Organization and in regulatory assessments by the European Medicines Agency and U.S. Food and Drug Administration.
Critiques mirror debates about registry completeness and timing raised by editors at BMJ, The Lancet, and PLOS Medicine and by researchers at Harvard T.H. Chan School of Public Health and Johns Hopkins Bloomberg School of Public Health. Specific controversies have concerned data quality, selective outcome reporting discussed in studies from Columbia University Irving Medical Center and McMaster University, and challenges in harmonizing fields with the WHO International Clinical Trials Registry Platform. High-profile ethical debates tied to research conduct in China have implicated institutions like Southern University of Science and Technology and prompted scrutiny from international bodies including the World Medical Association and the Committee on Publication Ethics.
Category:Clinical trial registries